Cara Therapeutics, Inc. (CARA) News
Filter CARA News Items
CARA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CARA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CARA News From Around the Web
Below are the latest news stories about CARA THERAPEUTICS INC that investors may wish to consider to help them evaluate CARA as an investment opportunity.
Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock SplitSTAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “Company”), today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock and reduction in the total number of authorized shares of its common stock from 200,000,000 to 16,666,667 will be effective as of 5:00 p.m. Eastern Time on Monday, December 30, 2024. The Company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market o |
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger AgreementProposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has recently completed an approximately $28 million private financing, which, together with Tvardi’s existing cash and Cara’s anticipated cash balance, is expected to fund the combined company into the second half of 2026 Tvardi anticipates reporting topline data in the second half of 2025 from two Phase 2 clinical programs utili |
Tessera gets sickle cell funding; Corvus shares slide on eczema dataThe Bill & Melinda Gates Foundation will invest up to $50 million in Tessera’s in vivo sickle cell therapy. Elsewhere, Cara agreed to a reverse merger and J&J had a drug application rejected. |
Cara Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsCara Therapeutics ( NASDAQ:CARA ) Third Quarter 2024 Results Key Financial Results Revenue: US$2.56m (down 48% from 3Q... |
Cara: Q3 Earnings SnapshotCARA) on Thursday reported a loss of $12.5 million in its third quarter. The Stamford, Connecticut-based company said it had a loss of 23 cents per share. Losses, adjusted for asset impairment costs, came to 15 cents per share. |
Cara: Q2 Earnings SnapshotOn a per-share basis, the Stamford, Connecticut-based company said it had a loss of 37 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 29 cents per share. |
Cara Therapeutics Announces Exploration of Strategic AlternativesPiper Sandler & Co. to act as financial advisorSTAMFORD, Conn., July 11, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that it has engaged Piper Sandler & Co. to act as its financial advisor for the process of exploring and reviewing strategic alternatives. “We are committed to evaluating a range of strategic options to maximize value for our shareholders,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. “As part of this effo |
Chipotle, McDonald's initiated: Wall Street's top analyst callsChipotle, McDonald's initiated: Wall Street's top analyst calls |
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the |
Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue EstimatesCara (CARA) delivered earnings and revenue surprises of -47.37% and 5.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock? |